Indiana University Researchers Earn $3.2 Million Grant to Develop, Improve Therapies for Pancreatic Cancer
Two Indiana University researchers have been awarded a multiyear, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.
Mark R. Kelley, PhD, Betty and Earl Herr Professor of Pediatric Oncology Research, and Melissa L. Fishel, PhD, Assistant Research Professor of Pediatrics, both at the IU School of Medicine, were awarded a 5-year grant (CA167291) from the National Cancer Institute of the National Institutes of Health. The two Indiana University Melvin and Bren Simon Cancer Center researchers will focus on investigating the signaling pathways and molecular mechanisms that contribute to pancreatic tumor progression and resistance to therapy.
Role of Tumor Microenvironment
In their laboratory research, Drs. Kelley and Fishel plan to block redox factor 1 (Ref-1), a protein crucial to regulating pancreatic tumor growth and metastasis, using a promising inhibitor that Dr. Kelley and colleagues have developed.
“We hope to better understand how this protein signals and functions in the tumor microenvironment as well as in the tumor cells. We’re hoping that if we can inhibit the function of Ref-1, we can blunt the tumor’s ability to live,” Dr. Fishel said.
Researchers have been learning that a tumor’s microenvironment plays a significant role in the life and death of a tumor. “We’re realizing that it’s not just the tumor that has to be treated,” Dr. Kelley added. “You have to treat the tumor and the surrounding support structure, its microenvironment. Because pancreatic cancer is hard to treat, we think Ref-1 is a viable target both in the tumor and the microenvironment.”
This latest pancreatic cancer project builds on Dr. Kelley’s ongoing research into using inhibitors to prevent cancer cells from repairing the damage caused by anticancer therapies.
Changing the Standard of Care
Drs. Kelley and Fishel will collaborate with other IU Simon Cancer Center researchers, including internationally recognized cancer researcher Murray Korc, MD, the Myles Brand Professor of Cancer Research at the IU School of Medicine and Director of the Indiana University-Purdue University Indianapolis Pancreatic Cancer Signature Center.
The research team also includes Theresa Guise, MD, Jerry and Peggy Throgmartin Professor of Oncology, and Mircea Ivan, MD, PhD, Assistant Professor of Medicine, both at the IU School of Medicine. Dr. Guise is an expert on tumor microenvironment and metastatic disease, while Dr. Ivan is an expert in hypoxia, a condition in which there is a decrease in the oxygen supply. Pancreatic tumors are hypoxic, which makes them more aggressive and difficult to treat.
“Our hope and goal is to change the standard of care because it’s not working,” Dr. Fishel said. “Our hope is to bring a new therapy—or a new one that would be used in conjunction with a current therapy—to make inroads against this disease. Even if a new therapy doesn’t kill the tumor, if it can penetrate the microenvironment to help other drugs get to the tumor, that would be beneficial.” ■